+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 65 Pages
  • April 2023
  • GlobalData
  • ID: 1292044
Ligand Pharmaceuticals Inc (LGND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help biopharmaceutical companies in the discovery and development of medicines. Its major research technologies include formulation science, structure-based drug design, antibody discovery technologies and liver targeted pro-drug technologies, which assist pharmaceutical companies in securing approval for prescription drugs. Its technologies and research capabilities contributed to the development of a diversified portfolio of biotechnology and pharmaceutical products for the inflammatory, respiratory central nervous system, oncology, ophthalmology, hematology, musculoskeletal disorder, and osteoporosis, among others. Ligand also offers late-stage development, regulatory management, and commercialization support in partnership with other pharmaceutical companies. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc Key Recent Developments

  • Feb 06, 2023: Ligand to Report Fourth Quarter Financial Results on February 22
  • Dec 05, 2022: Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
  • Nov 01, 2022: Ligand announces completion of OmniAb Spin-Off
  • Oct 03, 2022: Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Ligand Pharmaceuticals Inc - Key Facts
  • Ligand Pharmaceuticals Inc - Key Employees
  • Ligand Pharmaceuticals Inc - Key Employee Biographies
  • Ligand Pharmaceuticals Inc - Major Products and Services
  • Ligand Pharmaceuticals Inc - History
  • Ligand Pharmaceuticals Inc - Company Statement
  • Ligand Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Ligand Pharmaceuticals Inc - Business Description
  • Other Break-up: Captisol - Covid
  • Performance
  • Other Break-up: Captisol Sales
  • Performance
  • Other Break-up: Contract Revenue
  • Performance
  • Other Break-up: Royalties
  • Performance
  • R&D Overview
  • Ligand Pharmaceuticals Inc - Corporate Strategy
  • Ligand Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Ligand Pharmaceuticals Inc - Strengths
  • Ligand Pharmaceuticals Inc - Weaknesses
  • Ligand Pharmaceuticals Inc - Opportunities
  • Ligand Pharmaceuticals Inc - Threats
  • Ligand Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Ligand Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 06, 2023: Ligand to Report Fourth Quarter Financial Results on February 22
  • Dec 05, 2022: Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
  • Nov 01, 2022: Ligand announces completion of OmniAb Spin-Off
  • Oct 03, 2022: Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination
  • Aug 08, 2022: Ligand Reports Second Quarter 2022 Financial Results
  • Jun 29, 2022: Ligand Pharmaceuticals appoints Jason Haas to its Board of Directors
  • May 04, 2022: Ligand Reports First Quarter 2022 Financial Results
  • Feb 17, 2022: Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Ligand Pharmaceuticals Inc, Key Facts
  • Ligand Pharmaceuticals Inc, Key Employees
  • Ligand Pharmaceuticals Inc, Key Employee Biographies
  • Ligand Pharmaceuticals Inc, Major Products and Services
  • Ligand Pharmaceuticals Inc, History
  • Ligand Pharmaceuticals Inc, Other Locations
  • Ligand Pharmaceuticals Inc, Subsidiaries
  • Ligand Pharmaceuticals Inc, Key Competitors
  • Ligand Pharmaceuticals Inc, Ratios based on current share price
  • Ligand Pharmaceuticals Inc, Annual Ratios
  • Ligand Pharmaceuticals Inc, Interim Ratios
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Ligand Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Ligand Pharmaceuticals Inc, Performance Chart (2018 - 2022)
  • Ligand Pharmaceuticals Inc, Ratio Charts
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Trianni Inc
  • Atara Biotherapeutics Inc
  • TransGenic Inc
  • AbCellera Biologics Inc
  • Trianni Inc
  • Verrow Pharmaceuticals Inc
  • Gilead Sciences Inc
  • Regeneron Pharmaceuticals Inc
  • Ablexis LLC
  • TransGenic Inc
  • Atara Biotherapeutics Inc
  • Regeneron Pharmaceuticals Inc
  • Verrow Pharmaceuticals Inc
  • Gilead Sciences Inc
  • Ablexis LLC
  • AbCellera Biologics Inc